United Kingdom· GB-APID-22621011000001109
Bezafibrate 200mg tablets
A bezafibrate product containing bezafibrate, registered in United Kingdom by DE Pharmaceuticals. The same ATC class is registered in 10 of our 19 countries.
Checked against NHS dm+d (United Kingdom) on
Informational only — not a medical device.
Where it is registered
Bezafibrate is registered in 10 of 19 countries.
Countries holding a registration under ATC C10AB02 (bezafibrate), each read from that country’s own register.
- This record: United Kingdom, from NHS dm+d (United Kingdom)
- 6 of them publish a price we can compare per daily dose
Bezafibrate · ATC C10AB02
10 / 19 countries
- Belgiumprice
- Canada
- Finlandprice
- Franceprice
- Germany
- Italyprice
- Netherlands
- Norwayprice
- Switzerlandprice
- United Kingdom
Price per daily dose
What a daily dose of bezafibrate costs, country by country.
Normalised to the WHO defined daily dose (0.6 g), the median price runs from $0.29 in France to $1.19 in Switzerland — a ×4.1 gap.
- 3 markets with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Bezafibrate · price per daily dose (0.6 g)
USD · FX 28 Sept 2026
- CH Switzerland$1.19
- IT Italy$0.44
- FR France$0.29
The record
At a glance
NHS dm+d (United Kingdom)- Active substance
- Bezafibrate
- Manufacturer
- DE Pharmaceuticals
- Country
- United Kingdom (GB)
- ATC code
- C10AB02
- ATC class
- Bezafibrate
- Defined daily dose
- 0.6 g, O
- Reimbursed
- Not published by this register
- Source register
- NHS dm+d (United Kingdom)
- Last checked
- September 13, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Bezafibrate in 11 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- NorwayBezafibrate tevaTeva B.V.
- GermanyBezafibrat AlAliud Pharma Gmbh
- NetherlandsBezalip Retard 400 mg, tabletten met gereguleerde afgifteEU-Pharma B.V.
- SpainDIFATEROL RETARD 400 mg COMPRIMIDOS DE LIBERACION PROLONGADALaboratorios Bial S.A.
- FinlandBezafibrat GenericsGenerics (UK) Limited
- SwedenBezalip 200 mg Filmdragerad tablettActavis Group PTC ehf.
- CanadaBEZALIP SRALLERGAN INC
- SwitzerlandCedur Retard
Authorised across Europe · EMA
The same active substance is authorised in 14 EEA countries. Names it is sold under:
- Austria · Bezalip Retard, Bezastad
- Belgium · Cedur, Eulitop
- Cyprus · Lacromid, Zafibral
- Germany · Bezafibrat Al, Bezafibrat Retard Al
- Spain · Eulitop, Eulitop Retard
- Finland · Bezalip
- France · Befizal, Befizal L.P.
- Hungary · Bezalip
- Italy · Bezalip
- Luxembourg · Cedur, Eulitop
- Netherlands · Bezafibrate Aurobindo
- Portugal · Bezalip, Bezalip Retard
- Romania · Bezafibrat Arena
- Sweden · Bezalip, Bezalip Retard
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of NHS dm+d (United Kingdom). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/b76b602d-d453-4521-8c55-6d039b7e741c GET /v1/drugs/b76b602d-d453-4521-8c55-6d039b7e741c?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"apid": "22621011000001109",
"desc": "Bezafibrate 200mg tablets (DE Pharmaceuticals)",
"form": "Oral tablet",
"vpid": "42206811000001104",
"source": "dmd",
"vtm_id": "774852009",
"strength": "200 mg",
"substance": "Bezafibrate",
"ingredient": "Bezafibrate",
"supplier_code": "2268901000001109"
}See everything about bezafibrate.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.